First reported recovery and genomic characterization of a previously uncharacterized Mycobacterium species from human blood cultures in an immunocompromised patient: A case report
Abstract
Mycobacteremia is an uncommon opportunistic infection in immunocompromised hosts. We report the recovery of a previously uncharacterized Mycobacterium species from two independent blood culture sets obtained from an immunocompromised patient with persistent fever. She presented with persistent fever, and two independent blood culture sets yielded a Mycobacterium species. No focal source of infection was identified. Initial identification by MALDI-TOF mass spectrometry suggested Mycobacterium diernhoferi; however, species-level identification could not be confirmed by molecular methods. Whole-genome sequencing demonstrated that the isolate could not be assigned to any currently recognized Mycobacterium species. Average nucleotide identity analysis showed 90.5% similarity to M. diernhoferi and 84.4% to Mycobacterium frederiksbergense, suggesting a previously uncharacterized species. Combination antimicrobial therapy was followed by resolution of fever and no recurrent positive blood cultures during treatment. Although the patient ultimately died because of progression of the underlying hematological malignancy, the patient showed sustained clinical improvement without recurrent positive blood cultures during therapy. To our knowledge, this is the first reported recovery of this genomically distinct Mycobacterium species from human blood cultures. This case highlights the value of whole-genome sequencing in recognizing previously uncharacterized Mycobacterium species recovered…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.